Gene Therapy Rare Disease Deal Benchmarks

Median Upfront

$126M

Range: $49M - $213M

Total Deal Value

$1.2B

Range: $575M - $1.8B

Royalty Rate

6.2% - 12.4%

Tiered up to 16.4%

Dev Milestones

$375M

Range: $184M - $563M

Model Your Deal

Market Analysis

Gene therapy for rare diseases represents the highest-value intersection of modality and therapeutic area in biopharma licensing. Phase 1 gene therapy deals for orphan indications carry a median total deal value of $1.2B, with upfront payments of $126M. The curative one-time treatment model, combined with orphan drug exclusivity and premium pricing ($1M-$3.5M per patient), creates compelling deal economics even at early clinical stages.

Development milestones average $375M, reflecting the extensive de-risking required around vector tropism, transgene expression durability, and immunogenicity management. Regulatory milestones of $289M reward the accelerated approval pathways (surrogate endpoints, smaller trial sizes) available to orphan gene therapies. Commercial milestones reach $407M.

Royalty rates for rare disease gene therapy licensing range from 6.2% to 12.4% at the base tier. The unique economics of one-time curative treatments at $1M+ price points mean that commercial milestones are often structured around patient counts and treatment center expansion rather than traditional revenue thresholds. Zolgensma ($2.1M per treatment) and Hemgenix ($3.5M per treatment) set the pricing precedent.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What are typical deal terms for rare disease gene therapy?

Phase 1 rare disease gene therapy deals average $126M upfront with $1.2B total deal value. The 11/89 upfront/milestone split reflects early-stage clinical risk balanced against transformative curative potential.

How does orphan drug designation affect gene therapy deal terms?

Orphan drug designation provides 7 years US market exclusivity, FDA fee waivers, and 25% tax credit on clinical trial costs. For gene therapies specifically, the limited competition window combined with $1M-$3.5M per-patient pricing creates a highly favorable commercial profile that drives premium deal valuations.

What are the key risks in rare disease gene therapy deals?

Primary risks include durability of transgene expression (especially for AAV-based approaches), immunogenicity limiting re-dosing potential, manufacturing scalability of viral vectors, and payer access challenges at $1M+ price points. These risks are reflected in the milestone-weighted deal structures.

How do AAV gene therapy deals compare to gene editing deals in rare disease?

AAV gene therapy deals benefit from clinical validation (Zolgensma, Hemgenix approvals) but face re-dosing limitations. Gene editing platforms (CRISPR, base editing) offer potentially permanent cures but are earlier stage. Both command similar total deal values, though gene editing platforms may attract higher upfronts due to multi-indication potential.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.

Start Calculating

Gene Therapy Rare Disease Deal Benchmarks

Market Analysis

Full Benchmark Analysis

Customize these benchmarks for your asset

Frequently Asked Questions

Full Benchmark Analysis

Related Benchmarks

Rare Disease Overview

ERT Deal Benchmarks

Gene Therapy Deals (Oncology)

Preclinical Deal Benchmarks

Ready to Calculate Your Deal Terms?